%20(002)_edited.jpg)
David Fitzgerald
Director of Policy and Strategy for the NHS Cancer Programme, NHS England
David became the Director of Policy and Strategy for the NHS Cancer Programme in January 2018. He joined NHS England after four years in the Cabinet Office Implementation Unit, where he led the social policy team which advised the Prime Minister on the delivery of her top priorities in areas including health, education, skills, housing and welfare. From 2008 to 2013, David worked at the Department for Education, first as bill manager for the Apprenticeships, Skills, Children and Learning Bill and then as head of Childcare Funding Division, where he led the implementation of the coalition government’s commitment to extend free childcare to two-year-olds from lower income families. Before that, David spent 12 years at the Department for Culture, Media and Sport where he worked on arts, sport and gambling policy, and as Private Secretary to the Arts Minister.
Brian Duggan
Strategic Partnership Policy Director,
Association of the British Pharmaceutical Industry (ABPI)
Brian Duggan is the strategic partnership policy director for the Association of British Pharmaceutical Industry (ABPI) and is responsible for building strategic relationships across the sector to improve the UK’s ability to generate, attract, and benefit from biomedical innovation. Prior to joining the ABPI, Brian worked for NHS England as chief of staff for the national medical director, Professor Stephen Powis, having previously held the roles of head of medicines policy and senior strategy & policy advisor, supporting EU Exit and Covid response for medicines.
Dr Max Brodermann
Haematology Registrar at UCLH and Trustee, Cancer52
Max Brodermann is a haematology registrar at University College Hospital and a trustee of Cancer52. Working as a clinical academic, he has a particular interest in leukaemia and is currently researching new, targeted therapies. Max is passionate about education, improving the patient experience, and working towards better outcomes for all those with rare and less common cancers.